Class | Mechanism | Use | Problems |
Bulk-forming laxatives (cellulose or psyllium seeds) | Increases mass and water content of stool Decreases transit time | Should always be considered; may be useful in changing character of the effluent from a functioning stoma |
|
Osmotic cathartics (magnesium salts, sodium salts, lactulose, sorbitol, polyethylene glycol) | Increases water in the bowel Decreases transit time Lactulose/sorbitol attracts water into colon, acidifies contents Polyethylene glycol attracts water into the colon | Often used for bowel cleansing before medical procedures Lactulose and sorbitol have a slower onset and are commonly selected for long-term use; dose must be adjusted to effect Polyethylene glycol is not absorbed, has a slower onset, and the powder formulation also is commonly used for long-term therapy; dose must be adjusted to effect |
|
Surfactants (docusate) | Facilitates mixture of fat and stool | Usually combined with a contact cathartic as a first-line therapy for opioid-induced constipation |
|
Contact cathartics diphenylmethane drugs (bisacodyl) Anthraquinone drugs (cascara, senna) | Increases peristalsis Reduces absorption of water and electrolytes from intraluminal contents | May be used for acute or chronic therapy Often a first-line approach for long-term management, including prophylaxis when opioid therapy is initiated |
|
Opioid antagonists | Opioid antagonist | Goal is "bowel withdrawal" without concurrent systemic withdrawal | |
Subcutaneous methylnaltrexone | Opioid-induced constipation in refractory cases; does not cause systemic withdrawal symptoms |
| |
Oral naloxegol | Opioid-induced constipation; does not cause systemic withdrawal symptoms |
| |
Oral naldemedine | Opioid-induced constipation; does not cause systemic withdrawal symptoms |
| |
Oral naloxone | Opioid-induced constipation; parenteral formulation has been given orally, but the optimal dose and schedule are unknown |
| |
Fixed combination of extended-release oral oxycodone and naloxone (2:1 ratio) | Chronic pain requiring around-the-clock opioid treatment and prevention or relief of opioid-induced constipation |
| |
Chloride channel activator Lubiprostone | Locally acting type 2 chloride channel (ClC-2) activator | Treatment of opioid-induced constipation |
|
Guanylate cyclase-C agonist (linaclotide) | Intracellular and extracellular cyclic guanosine monophosphate concentrations are increased from the binding of guanylate cyclase-C on the luminal surface of the intestinal epithelium resulting in chloride and bicarbonate secretion into the intestinal lumen Gastrointestinal transit is increased from an increase in intestinal fluid | Refractory opioid-induced constipation (off-label) |
|
Do you want to add Medilib to your home screen?